Article
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Blood - 2 Jul 2026
Zent Clive S, Tiacci Enrico, Kreitman Robert J, Tadmor Tamar, Tallman Martin S, Wörmann Bernhard, Andritsos Leslie A, Arons Evgeny, Banerji Versha, Barrientos Jacqueline C, Bhat Seema A, Blachly James S, Broccoli Alessandro, Call Timothy G, Dearden Claire, Demeter Judit, Dietrich Sascha, El-Sharkawi Dima, Fagarasanu Andrei, Falini Brunangelo, Forconi Francesco, Gerrie Alina S, Gladstone Douglas E, Gozzetti Alessandro, Hampel Paul J, Hermel David J, Iyengar Sunil, Johnston James B, Juliusson Gunnar, Kipps Thomas J, Lauria Francesco, Lozanski Gerard, Parikh Sameer A, Park Jae H, Polliack Aaron, Quest Graeme, Rai Kanti, Ravandi Farhad, Robak Tadeusz, Rogers Kerry A, Saven Alan, Seymour John F, Tam Constantine S, Troussard Xavier, Zenz Thorsten, Zinzani Pier Luigi, Grever Michael R
Abstract excerpt
ABSTRACT: Hairy cell leukemia (HCL) and HCL variant (HCLv) are distinct, rare, and chronic splenic B-cell lymphomas/leukemias that partially overlap in clinicopathologic presentation but differ in genetic basis, prognosis, and management. HCL is caused by the BRAF-V600E kinase-activating mutation in >95% of the patients, usually has excellent responses to chemotherapy with purine analogues, and is also amenable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.